CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
- CX-904 (EGFRxCD3) initial Phase 1 dose escalation data anticipated first half of 2024 - - IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) anticipated in the fourth quarter of 2023 - - Management to …